Annual Review Course Bundle (2018)

Austin, TX US
June 1, 2018 to June 3, 2018

In preparation for the American Board of Urology (ABU) Qualifying (Part 1) Examination, residents need to have basic urologic knowledge to prepare them for the ABU examinations. To fulfill this need, the American Urological Association (AUA) developed this course to disseminate current urologic knowledge. This course is also of interest to practicing urologist preparing for the Recertification Examination as well as others, including allied health professionals, looking for a thorough review of basic urologic topics.

This extended learning option includes non-CME Webcast  access featuring simultaneous presentation slides and audio recorded from the Live Course and includes access to online course materials.

 

 

 

 

Target Audience

  • APN/PA
  • Resident
  • Urologist

Learning Objectives

At the conclusion of this course, participants will be able to:

  1. Apply basic, generally-accepted urological practices for superior patient care.
  2. Demonstrate core knowledge of urology necessary for Part I of the American Board of Urology (ABU) qualifying examination and for the recertification examination.
  3. Utilize AUA Guidelines for appropriate patient evaluation and management.
Course summary
Available credit: 
  • 26.75 AMA PRA Category 1 Credit™
  • 26.75 Non-Physician Participation
Course opens: 
03/09/2018
Course expires: 
06/03/2021
Event starts: 
06/01/2018 - 7:30am EDT
Event ends: 
06/03/2018 - 5:00pm EDT
Price:
$1,865.00
Rating: 
0

Friday, June 1, 2018

6:30 a.m. Registration/Breakfast
7:30 a.m.Introduction 
Howard B. Goldman, MD, and Wade J. Sexton, MD

Penile and Urethral Cancer

7:45 a.m. 

 

 

 

Robert G. Uzzo, MD 
  • Epidemiology
  • Diagnosis and Staging
  • Imaging and Treatment

Renal and Ureteral Tumors

8:30 a.m.

 

 

 

 

Robert G. Uzzo, MD

  • Epidemiology, Anatomy, Diagnosis and Imaging (Including Evaluation of Renal Masses)
    • Treatment of Localized Disease (including Role of Partial Nephrectomy)
    • Treatment of Metastatic Disease
    • Transitional Cell Carcinoma
9:45 a.m.Break

Bladder Cancer

10:00 a.m.

 

 

 

Michael A. O'Donnell, MD 
  • Epidemiology, Anatomy, Diagnosis and Imagingo
    • Treatment of NMIBC/ Superficial Disease Managment
    • Bladder Cancer Test Questions

11:00 a.m.

 

 

 

 

Angela M. Smith, MD      
  • Staging and Risk Stratification of Muscle Invasive Bladder Cancer
  • Multidisciplinary Treatment including Radical Cystectomy, Lymphadenectomy, Peri-Operative Chemotherapy and Chemoradiation Therapy
  • Metabolic Derangements that Occur with Diversions
  • Other Bladder Sparing Treatments
  • Treatment of Metastatic Disease
12:10 p.m.Bladder Cancer Questions 
Michael A. O'Donnell, MD and Angela M. Smith, MD
12:30 p.m.Lunch

1:30 p.m.

 

 

Howard B. Goldman, MD 
  • Applied Anatomy
  • Embryology

BPH

3:15 p.m.

 

 

 

Claus G. Roehrborn, MD
  • Evaluation
  • Medical Management
  • Surgical Management
3:40 pmBreak

Prostate Cancer

3:55 p.m.

 

 

 

 

Adam S. Kibel, MD 
  • Diagnosis and Screen, Staging, Imaging (including PSA Screening Controversies)
  • Treatment of Localized Cancer (U.S. Stages A and B), Watchful Waiting, Radiation, Interstitial Irradiation, Surgery, Cryosurgery and Hormonal Therapy)
  • Treatment of Advanced Cancer (U.S. Stages C and D) and Treatment of Radiation Failure
  • DVT Prophylaxis

Adrenal

5:05 p.m.

 

 

 

Jay T. Bishoff, MD 
  • Epidemiology, Diagnosis and Imaging (including Cushings, Hyperaldosteronism, Pheochromocytoma, Cancer and the Incidentally Found Adrenal Mass)
  • Management (including Pheochromocytoma, Cancer, Hyperaldosteronism, Incidentaloma and Metastatic Disease)
5:50 p.m.Meeting Adjourns for the Day

Saturday, June 2, 2018

6:30 a.m.  Breakfast
7:00 a.m.Exam Overview, Test Taking Logistics, and ABU Process
TBD

Pediatric Urology

7:30 a.m.

 

 

 

 

Andrew J. Kirsch, MD 
Congenital Urinary Tract Abnormalities 
  • UPJ Obstruction, UVI Obstruction (megaureter)
  • Ureteroceles
  • Cystic Kidney Disease
  • Posterior Urethral Valves
  • Prune Belly Syndrome
  • Vesicoureteral Reflux

8:30 a.m.

 

 

 

Armando J. Lorenzo, MD 
Pediatric Urinary Incontinence and Bladder Disorders 
  • Voiding Dysfunction and Neurogenic Bladder 
  • Developmental Anomalies of the Bladder
  • Urinary Tract Infection and Secondary Reflux
  • Management of Neurogenic and Non-Neurogenic Bladder

9:00 a.m.

 

 

 

Andrew J. Kirsch, MD
Disorders of the Genitalia/Scrotum
  • Disorders of Sexual Differentiation
  • Hypospadias
  • Undescended Testicle, Hydroceles, Hernias

9:45 a.m.

 

 

 

Armando J. Lorenzo, MD 
Pediatric Urological Oncology 
  • Wilm's Tumor and other Renal Tumors
  • Rhabdomyosarcoma
  • Neuroblastoma
  • Testis Tumors
10:15 a.m.Break
10:30 a.m.Pediatric Review Questions
Andrew J. Kirsch, MD and Armando J. Lorenzo, MD 

Urolithiasis

11:00 a.m.

 

 

Sara L. Best, MD 
  • Epidemiology, Pathophysiology
  • Evaluation and Medical Management

Infection and Inflammation

12:00 p.m.

 

 

Hannah R. Choate, MD 
  • Interstitial Cystitis
  • Sexually Transmitted Diseases (Gonorrhea, Chlamydia, AIDS and others)
12:45 p.m. Lunch

Urolithiasis

1:45 p.m.

 

 

Sara L. Best, MD
  • Surgical Management of Stone Disease

Laparoscopy

 

2:30 p.m.

 

Jay T. Bishoff MD
  • Physiology and Complications
3:00 p.m.Break

Urinary Tract Infection

3:15 p.m.Michel Y. Pontari, MD

Renal Medicine

4:15 p.m.

 

 

Hannah R. Choate, MD 
  • Renal Transplantation
  • Renal Vascular Disease
  • Renal Physiology (including Fluid and Electrolytes)
5:45 p.m.Meeting Adjourns for the Day

Sunday, June 3, 2018

6:30 a.m.Breakfast

Female Urology, Urodynamics and Neurology

7:00 a.m.

 

Stephen R. Kraus, MD    
Neurourology

7:45 a.m.

 

Urodynamics Tracing Review 
Stephen R. Kraus, MD and Howard B. Goldman, MD

8:15 a.m.

 

 

 

 

Howard B. Goldman, MD 
  • Overactive Bladder/Urgency Incontinence 
  • Stress Urinary Incontinence
  • Pelvic Organ Prolapse
  • Vaginal Masses/Urethral Diverticulum
  • Urinary Fistula
9:30 a.m.Break

Erectile Dysfunction

9:45 a.m.

 

 

 

John P. Mulhall, MD
  • Physiology of Erection, Pathophysiology of Erectile Dysfunction
  • Evaluation and Management of Erectile Dysfunction
  • Pathophysiology, Evaluation and Management of Priapism Pathophysiology, Evaluation and Management of Peyronie's Disease

Testicular Tumors

10:45 a.m.

 

 

 

 

Wade J. Sexton, MD
  • Epidemiology, Diagnosis, Staging and Imaging (including the Role of Markers and CIS)
  • Treatment of Seminoma
  • Treatment of Non-Seminomatous Germ Cell Tumors (including Controversy Regarding Stage A Management, Risk Factors for Recurrence, Algorithms for Stages A,B, and C)
12:00 p.m.Lunch

Infertility

1:00 p.m.

 

 

 

 

Paul  J. Turek, MD 
  • Physiology and Pathophysiology of Male Reproduction
  • Evaluation of the Infertile Male
  • Treatment of the Infertile Male (Surgical and Non-surgical)
  • Hypogonadism
  • Testosterone Replacement
2:30 p.m.Break

GU Radiology

2:45 p.m.

 

 

 

 

 

Brian R. Herts, MD
  • Basics of MR, CT, US, VCUG
  • Solid and Cystic Renal Masses (CT and MR)
  • Transitional Cell Carcinoma
  • Prostate MR
  • Adrenal Imaging
  • Scrotal Imaging
  • Retroperitoneal Tumors
  • Radiation Basic Principles

Urologic Trauma

4:00 p.m.

 

 

 

Jay Simhan,  MD 
  • Renal and Ureteral Trauma: Evaluation and Management
  • Bladder and Urethral Trauma: Evaluation and Management
  • Genital Trauma: Evaluation and Management
  • Urethral Stricture Disease
5:00 p.m.Course Adjourns
Hyatt Regency Austin
208 Barton Springs
Austin, TX 78704
United States

To hold a reservation, a major credit card number must be provided.

$195 single/double occupancy.  Make your reservation online or call 800-233-1234.  Reference the AUA Annual Review Course when making your reservation to receive the special group rate.

Cut-off Date: Thursday, May 10, 2018. Once the AUA group block is full, which may be prior to the cut-off date, the AUA is unable to guarantee rooms at this rate or at this hotel.

Check-in: 4 p.m.

Check-out: 11 a.m.

Parking: The Hyatt Regency Austin provides daily self-parking for $24.00 per day. Valet parking is priced at $19.00 for daytime parking with no in-and-out privileges and $32.00 for overnight valet. Prices are subject to change.

Travel

Transportation: The Hyatt Regency Austin is located approximately 11 miles/18 minute from Austin-Bergstrom International Airport.  Taxi Cost: $20.00 - $27.00 one-way. Travel time is dependent on time of day and traffic conditions. Additional transportation information and directions.

Car Rental: Hertz is pleased to offer special discounted car rental rates to AUA course and meeting attendees. Make your car rental reservation online or call 1-800-654-2240 and mention the AUA discount code CDP# 1953476.

image

NameCompanyRoleFinancial
Sara L. Best, MDAmerican Urological AssociationMeeting Participant or LecturerYes
Endourological SocietyMeeting Participant or LecturerYes
Jay T. Bishoff, MDMyriad GeneticsConsultant or Advisor, Scientific Study or TrialYes
Hannah R. Choate, MDNothing to discloseYes
 Howard B. Goldman, MD, FACSallerganConsultant or AdvisorYes
NuvectraConsultant or AdvisorYes
AxonicsConsultant or AdvisorYes
NewUroConsultant or AdvisorYes
GalvaniConsultant or AdvisorYes
bionessScientific Study or TrialNo
CookScientific Study or TrialYes
MedtronicConsultant or Advisor, Meeting Participant or Lecturer, Scientific Study or TrialYes
Brian Herts, MDSiemens HealthineersScientific Study or TrialYes
Adam S. Kibel, MDProfoundConsultant or AdvisorYes
JanssenConsultant or AdvisorYes
ConfirmMDxConsultant or AdvisorYes
PfizerConsultant or AdvisorYes
Andrew J. Kirsch, MDNothing to discloseYes
 Stephen R. Kraus, MDLaborieOther : Course Director and Teaching FacultyYes
AllerganConsultant or AdvisorYes
AstellasConsultant or Advisor, Meeting Participant or LecturerYes
Gary E. LemackRoivantConsultant or AdvisorYes
AllerganConsultant or Advisor, Meeting Participant or LecturerYes
 Armando J. Lorenzo, MD  Yes
John P. Mulhall, MDAssociation of Peyronie's Disease Advocates (APDA)Leadership PositionYes
PfizerConsultant or Advisor, Meeting Participant or Lecturer, Scientific Study or TrialYes
Michael A. O'Donnell, MDViventiaConsultant or AdvisorYes
Fidia PharmaceuticalsConsultant or AdvisorYes
Abbott MolecularScientific Study or TrialYes
TelestaConsultant or AdvisorYes
Roche/GenentechScientific Study or TrialYes
Medical EnterprisesConsultant or Advisor, Scientific Study or TrialYes
TheralaseConsultant or Advisor, Investment InterestYes
Spectrum PharmaceuticalsConsultant or AdvisorYes
PhotocureScientific Study or TrialNo
Michel A. Pontari, MDLillyConsultant or AdvisorYes
aquinoxConsultant or Advisor, Scientific Study or TrialYes
allerganConsultant or AdvisorYes
Claus G. Roehrborn, MDGlaxo Smith KlineConsultant or Advisor, Meeting Participant or LecturerYes
Southwest Oncology GroupScientific Study or TrialYes
NIDDKHealth Publishing, Scientific Study or TrialYes
nymoxConsultant or AdvisorYes
Procept BioroboticsConsultant or Advisor, Scientific Study or TrialYes
Boston ScientificConsultant or AdvisorYes
NxtheraScientific Study or TrialNo
AstellasScientific Study or TrialYes
NeotractConsultant or Advisor, Scientific Study or TrialYes
NERIConsultant or Advisor, Scientific Study or TrialYes
CALGB Clinical Trial GroupScientific Study or TrialYes
ProtoxConsultant or Advisor, Scientific Study or TrialYes
Wade J. Sexton, MDNothing to discloseYes
Jay Simhan, MDBoston ScientificMeeting Participant or LecturerYes
ColoplastMeeting Participant or LecturerYes
Angela M. Smith, MDAHRQScientific Study or TrialYes
PCORIScientific Study or TrialYes
Paul J. Turek, MDMandalMedLeadership PositionYes
Medical Board of CaliforniaConsultant or AdvisorYes
HealthLoop.comConsultant or Advisor, Investment InterestYes
Doximity, IncConsultant or Advisor, Investment InterestYes
Episona, IncConsultant or AdvisorYes
Cellarity Biotechnologies, IncLeadership Position, Investment Interest, Owner, Product DevelopmentYes
Contraline, IncConsultant or AdvisorYes
FutureFamily, IncConsultant or AdvisorYes
BioQuiddity, IncConsultant or Advisor, Investment InterestYes
Essential Beginnings, IncLeadership Position, Investment Interest, Owner, Product DevelopmentYes
Robert G. Uzzo, MDJanssenMeeting Participant or LecturerYes
PfizerMeeting Participant or LecturerYes
NovartisScientific Study or TrialYes
GenentechScientific Study or TrialYes

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 26.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


Available Credit

  • 26.75 AMA PRA Category 1 Credit™
  • 26.75 Non-Physician Participation

Price

Price:
$1,865.00
Please login or register to take this course.